Genetic Markers SPOP and CHD1 Identified as Key Determinants of Ferroptosis Sensitivity in Advanced Prostate Cancer

A new study from The University of Texas MD Anderson Cancer Center has identified two common genetic alterations that exert opposing influences on prostate cancer (搜索)搜索该疾病 susceptibility to ferroptosis, a regulated form of iron-dependent cell death. Published in Nature Communications, the findings position SPOP (搜索)搜索该靶点 mutations and CHD1 (搜索)搜索该靶点 deletions as potential biomarkers that could guide patient selection for emerging ferroptosis-targeting therapies, particularly in tumors resistant to conventional treatments.

The study was led by Di Zhao, Ph.D., associate professor, and Boyi Gan, Ph.D., professor, both of Experimental Radiation Oncology at MD Anderson.

"Prostate cancer (搜索)搜索该疾病 is such a genetically diverse cancer that there are many possible treatment options, so getting patients on the right treatment as quickly as possible is crucially important," Zhao said. "The two genetic findings in this study could help identify some patients that are more likely to respond, as well as some patients that are significantly less likely."

SPOP (搜索)搜索该靶点 Mutations Sensitize Tumors to Ferroptosis

SPOP (搜索)搜索该靶点 is a known tumor suppressor gene whose normal function is to prevent tumor development; mutations disrupt this protective role. The MD Anderson team discovered that one downstream consequence of SPOP disruption is an increase in the enzyme ACSL4 (搜索)搜索该靶点 (acyl-CoA synthetase long-chain family member 4), which loads polyunsaturated fatty acids into cell membranes. Since ferroptosis-inducing therapies target precisely this lipid oxidation process, SPOP-mutant prostate cancers demonstrate heightened vulnerability to ferroptotic cell death.

This mechanistic link is further supported by a comprehensive review of ferroptosis-based therapy for prostate cancer (搜索)搜索该疾病, which identifies ACSL4 (搜索)搜索该靶点 as a central promoter of ferroptosis sensitivity. The review notes that ACSL4 promotes incorporation of polyunsaturated fatty acids into membrane phospholipids, increasing susceptibility to oxidation, while counter-regulatory enzymes such as stearoyl-CoA desaturase 1 (SCD1) generate monounsaturated fatty acids that stabilize membranes and protect against ferroptosis.

CHD1 (搜索)搜索该靶点 Deletions Confer Resistance, Statins May Overcome It

In contrast, CHD1 (搜索)搜索该靶点 deletions produce the opposite effect, causing a reduction in ACSL4 (搜索)搜索该靶点 levels and diminishing the vulnerability of cancer cells to ferroptosis. The study demonstrated that using a statin therapy—already approved for lowering cholesterol—restored ACSL4 levels in preclinical models, effectively re-sensitizing CHD1-deleted tumors to ferroptosis induction.

"Ferroptosis is a promising strategy for treating therapy-resistant cancers, but we still need to understand which tumors are most likely to benefit," Zhao said. "By identifying SPOP (搜索)搜索该靶点 mutations and CHD1 (搜索)搜索该靶点 deletions as key determinants of ferroptosis sensitivity, our findings provide a foundation for developing more precise and effective ferroptosis-based therapies."

The Ferroptosis Therapeutic Landscape

A common ferroptosis-inducing strategy currently under investigation in preclinical and early-phase studies involves GPX4 (搜索)搜索该靶点 inhibitors. These agents block glutathione peroxidase 4, an enzyme that prevents the types of fatty acid buildup leading to ferroptosis. Compounds such as RSL3查看药品详情, ML162, ML210, and FIN56 disrupt GPX4 activity, resulting in uncontrolled lipid peroxide accumulation. In preclinical prostate cancer (搜索)搜索该疾病 models, RSL3 significantly reduced tumor growth, particularly when combined with iron supplementation.

Alternative approaches focus on depleting glutathione—an essential cofactor for GPX4 (搜索)搜索该靶点—through agents such as Erastin, sulfasalazine, sorafenib, and buthionine sulfoximine. Additional strategies involve increasing intracellular iron levels using compounds like dihydroartemisinin and artemisinin, which amplify Fenton chemistry and lipid peroxidation.

Combination Strategies and the Tumor Immune Microenvironment

Combination therapy has emerged as a particularly promising direction. Ferroptosis inducers synergize with anti-androgen therapies such as enzalutamide查看药品详情 and darolutamide查看药品详情 by weakening antioxidant defenses, and they enhance responses to chemotherapy agents including cisplatin and docetaxel. The tumor immune microenvironment also plays a critical role: activated CD8⁺ T cells secrete interferon-γ, which suppresses SLC7A11 expression and promotes ferroptosis in tumor cells. Immune checkpoint blockade, particularly PD-1 inhibition, may amplify this effect, creating what researchers describe as an "immune–ferroptosis cycle."

Nanotechnology platforms offer additional opportunities for targeted delivery. PSMA-targeted nanoparticles carrying iron and RSL3查看药品详情, magnetic lipid nanoparticles delivering DECR1 siRNA, and manganese sulfide-based systems that generate reactive oxygen species directly within tumors have all demonstrated substantial tumor suppression with minimal off-target effects in early animal studies.

Toward Precision Ferroptosis Medicine

Despite the promise, significant challenges remain. Tumors can develop resistance through overexpression of GPX4 (搜索)搜索该靶点, SLC7A11, FSP1, and Nrf2, as well as through metabolic rewiring and adaptation to hypoxic microenvironments. No ferroptosis-specific therapy has yet advanced into routine clinical practice, and most current evidence derives from cell culture and animal models.

The MD Anderson findings address a critical gap by identifying genetic biomarkers that could enable more precise patient stratification. High expression of SLC7A11 or GPX4 (搜索)搜索该靶点 is associated with treatment resistance and may identify tumors most likely to benefit from ferroptosis-targeted therapies. Future tools may include ACSL4 (搜索)搜索该靶点 immunohistochemical scoring, lipidomics-based profiling, ferroptosis imaging probes, and machine learning-guided biomarker discovery—innovations that could maximize the therapeutic potential of ferroptosis-targeted interventions in castration-resistant prostate cancer (搜索)搜索该疾病, where conventional therapies frequently fail.